"Wanted for murder in Rome, hounded by creditors and cuckold husbands all over the Italian peninsula, and then finally chased across the Mediterranean Sea by the Knights of Malta, Caravaggio must have felt some degree of relief when he arrived on the shores of Sicily."
Read More At: https://rickzullo.com/caravaggio-in-sicily/
"The man who is slow to grasp things but who really tries hard is rewarded, equally he who does not cultivate his God-given intellectual ability is condemned for despising his gifts and sinning by sloth."
~St Isidore of Seville
Eli Lilly and Company's experimental intravenous drug donanemab "could slow the cognitive decline of patients with Alzheimer's disease," reports CNN, citing early clinical trial results, published today in The New England Journal of Medicine:The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science officer at the Alzheimer's Association, who was not involved in the study. "Out of 18 months, in comparison to the people that did not get the drug, these folks were declining six months slower," Carrillo said. "That's six more months of better cognition, better memories, better enjoyable times with your family...."
"This has a lot of potential," Carrillo added. "It could be a first step towards slowing more significantly, or stopping, cognitive decline in these earlier stages, which would really be transformational for our field..."
The researchers also looked at the drug's impact on the buildup of amyloid beta plaque and tau proteins, which are considered hallmarks of Alzheimer's disease. At 52 weeks, almost 60% of participants had reached amyloid-negative status, meaning their levels were at those of otherwise healthy people. At 76 weeks, amyloid plaque levels — measured in centiloids — decreased by 85 centiloids more than in those who received the placebo, the researchers reported...
"We are extremely pleased about these positive findings for donanemab as a potential therapy for people living with Alzheimer's disease, the only leading cause of death without a treatment that slows disease progression," Dr. Mark Mintun, Eli Lilly's vice president of pain and neurodegeneration, said in a January statement announcing the trial results...
Alzheimer's disease is the most common form of dementia, and currently affects 6.2 million Americans age 65 and older, according to the Alzheimer's Association.
“Man can only endure a certain degree of unhappiness; what is beyond that either annihilates him or passes by him and leaves him apathetic”
~Johann Wolfgang von Goethe
